Breast Cancer and Breast Health - Global Oncology Academy

17-24 of 24

The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Management of HR+, HER2- High-Risk EBC
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD; Erica L. Mayer, MD, MPH
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits

Previous
1
2
Next

2/2